BIRADS Classification and Management

BIRADS Categories and Definitions

• The American College of Radiology (ACR) defines BIRADS categories to categorize breast imaging findings based on their likelihood of malignancy, guiding further management decisions 1, 2
• Category 0: Incomplete Assessment - Needs additional imaging evaluation and/or prior mammograms for comparison, typically used in screening situations when additional views or ultrasound are needed for complete assessment 1, 3
• Category 1: Negative - No abnormalities found, the breasts are symmetric with no masses, architectural distortion, or suspicious calcifications present 1, 2
• Category 2: Benign Findings - Negative mammogram with benign findings such as calcifying fibroadenomas, oil cysts, lipomas, intramammary lymph nodes, vascular calcifications, implants, or architectural distortion clearly related to prior surgery 1, 4
• Category 3: Probably Benign - Findings have less than 2% likelihood of malignancy, short-interval follow-up (usually 6 months) is recommended to ensure stability 1
• Category 4: Suspicious Abnormality - Findings warrant biopsy consideration, risk of malignancy is widely variable but greater than category 3 and less than category 5 1
• Category 5: Highly Suggestive of Malignancy - Findings have a high probability (≥95%) of being cancer, examples include spiculated masses or malignant-appearing pleomorphic calcifications 1
• Category 6: Known Biopsy-Proven Malignancy - Added in the fourth edition of BI-RADS for lesions confirmed to be malignant through biopsy but before definitive therapies 1, 2

Clinical Application and Follow-up Recommendations

• For BIRADS 1-2, resume routine screening mammography in 1 year 3, 5
• For BIRADS 3, diagnostic mammograms at 6 months, then every 6-12 months for 1-2 years, if stable or resolved, resume routine screening, if changes occur, proceed to biopsy 5, 6
• For BIRADS 4-5, tissue diagnosis using core needle biopsy (preferred) or needle localization excisional biopsy with specimen radiograph 5, 6
• For BIRADS 6, management according to breast cancer treatment guidelines 5

Important Considerations

• The overall BIRADS assessment is based on the most worrisome findings when multiple abnormalities are identified 1, 2
• When both mammography and ultrasound are performed, the BIRADS categories represent the cumulative findings of both imaging modalities 1, 4
• The BIRADS assessment category may change based on subsequent imaging findings (increase, decrease, or remain the same) 1, 2
• Pathology-imaging concordance is essential when biopsies are performed, when pathology and imaging are discordant, repeat imaging and/or additional tissue sampling is recommended 5, 6

Breast Imaging Reporting and Data System (BI-RADS) Guidelines

Management Recommendations by Category

• The National Comprehensive Cancer Network recommends performing a unilateral diagnostic mammogram at 6 months, then bilateral mammography every 6-12 months for 1-2 years total before returning to routine screening for BI-RADS 3 lesions 7, 8
• The National Comprehensive Cancer Network suggests that core needle biopsy has a sensitivity of >97% and a specificity of 92-99% for breast cancer diagnosis 9
• The National Comprehensive Cancer Network recommends immediate biopsy instead of surveillance for patients with a strong family history of breast cancer, genetic predisposition, or other high-risk factors 7, 8
• The National Comprehensive Cancer Network advises that pathology-imaging concordance is mandatory, and discordant results require repeat breast imaging and/or additional tissue sampling 7, 8
• The American Cancer Society, as reported in Ca-A Cancer Journal for Clinicians, notes that timely follow-up is critical for BI-RADS categories 4 and 5, and the time between positive screening and biopsy is a key quality metric 9
• The National Comprehensive Cancer Network recommends managing BI-RADS 6 lesions according to breast cancer treatment guidelines 7, 8

Management of Incomplete Breast Imaging Evaluations

Initial Assessment and Diagnostic Approach

• The National Comprehensive Cancer Network recommends obtaining prior mammograms and performing a diagnostic mammogram with targeted ultrasound to complete the assessment for patients with incomplete breast imaging evaluations, as this represents an incomplete evaluation that requires additional imaging before any definitive management decision can be made 10
• For patients ≥30 years old with these findings, diagnostic mammogram plus ultrasound is the standard approach, and the diagnostic mammogram should include targeted views of the areas of concern identified on the screening ultrasound 11, 10

Management Based on Final Imaging Classification

• The American College of Radiology recommends reassigning BI-RADS category based on complete assessment, and the findings will be reclassified into a definitive BI-RADS category (1, 2, 3, 4, or 5), which will then dictate management 10
• For lesions that are likely simple cysts, resume routine annual screening mammography, as simple cysts are benign findings (BI-RADS 2) and require no further workup beyond routine screening 10, 11
• For hypoechoic nodules with distinct margins and parallel orientation that meet probably benign criteria, perform unilateral diagnostic mammogram at 6 months, then bilateral mammography every 6-12 months for 1-2 years total before returning to routine screening, with consideration for biopsy if clinically suspicious 11

Critical Considerations for Management

• The National Comprehensive Cancer Network advises against proceeding directly to biopsy or short-interval follow-up based solely on the screening ultrasound report, as the BI-RADS 0 designation explicitly indicates that the assessment is incomplete and additional imaging is mandatory before determining the appropriate management pathway 10
• If either nodule is palpable and there is lack of geographic correlation between clinical and imaging findings after complete diagnostic workup, core needle biopsy should be strongly considered regardless of the final BI-RADS category, as clinical findings take precedence 11

BI‑RADS 2 Management Recommendations

Routine Screening After BI‑RADS 2 Diagnosis

• For women aged ≥ 40 years with a BI‑RADS 2 (definitively benign) finding on mammography, the guideline recommends returning to routine annual screening mammography after 1 year, with no need for additional imaging or short‑interval follow‑up. 12 (National Comprehensive Cancer Network)

Use of Targeted Ultrasound When Palpable Findings Are Present

• If a palpable breast abnormality is identified and its correlation with the BI‑RADS 2 mammographic finding is uncertain, a targeted ultrasound may be performed to verify that the imaging finding truly accounts for the palpable concern. 13 (American College of Radiology)
• When the palpable abnormality clearly corresponds to the benign mammographic finding, targeted ultrasound is not required. 13 (American College of Radiology)

Distinction From BI‑RADS 3 (Probably Benign)

• BI‑RADS 2 lesions carry essentially 0 % malignancy risk, whereas BI‑RADS 3 lesions have a malignancy risk of < 2 % and therefore require short‑interval follow‑up at 6‑month intervals for 1–2 years. 12 (National Comprehensive Cancer Network)

Management of Focal Asymmetry Detected on Screening Mammography

Diagnostic Workup

• The NCCN guidelines recommend that any focal asymmetry identified on screening mammography should be evaluated immediately with diagnostic mammography that includes spot‑compression and magnification views, together with targeted breast ultrasound, to assign a definitive BI‑RADS category before any management decisions are made. 14
• Prior mammograms should be obtained for comparison whenever available; demonstrated stability of the focal asymmetry over time markedly lowers the suspicion for malignancy. 14

Management of BI‑RADS 1–2 (Negative or Benign)

• Patients whose focal asymmetry is classified as BI‑RADS 1 or 2 should resume routine annual screening mammography. 14
• If a palpable mass is present despite a negative imaging assessment, a focused ultrasound examination is advised to evaluate the clinical finding, because imaging alone may miss some cancers. 14

Management of BI‑RADS 3 (Probably Benign – <2 % Malignancy Risk)

• A unilateral diagnostic mammogram is performed at 6 months, followed by bilateral mammography every 6–12 months for a total surveillance period of 1–2 years. 14
• When the lesion remains stable or resolves during surveillance, the patient returns to routine screening. 14
• If the lesion enlarges or its imaging characteristics change, a tissue biopsy should be undertaken. 14
• In patients with a strong family history of breast cancer, known genetic predisposition, uncertain follow‑up compliance, or a strong preference for definitive diagnosis, an initial biopsy may be considered instead of imaging surveillance. 14

Management of BI‑RADS 4–5 (Suspicious or Highly Suggestive of Malignancy)

• Tissue diagnosis is mandatory; the preferred method is core‑needle biopsy, with needle‑localization excisional biopsy and specimen radiography as alternatives. 14
• Pathology‑imaging concordance must be confirmed; if benign pathology is discordant with suspicious imaging findings, surgical excision is required to avoid missed malignancy. 14

Imaging Modality Recommendations

• Digital Breast Tomosynthesis (DBT) can replace conventional diagnostic mammographic projections in the recall setting, as it has been shown to increase true‑positive detections while decreasing both false‑negative and false‑positive rates compared with standard diagnostic mammography. 15
• European guidelines advise the use of DBT rather than traditional diagnostic mammography views for women recalled for suspicious lesions. 15